Amgen rarely details much on international sales but did give a bit of background on Vectibix in Japan on the July 30 earnings call.
Amgen is only weeks away from an anticipated FDA approval for its PCSK9 cholesterol lowerer. Already approved in Europe, the drug is expected to quickly reap blockbuster sales. The biotech's current portfolio of products, along with cost cuts, have helped set the stage for a big year that could possibly include M&A.
Amgen, long criticized over its appetite for moonshot R&D projects, scaled back its research budget by more than 10% in the second quarter, part of a companywide effort to cut costs while advancing a make-or-break pipeline.
Amgen shocked the industry in May when it cut ties with an AstraZeneca-partnered psoriasis treatment after spotting alarming rates of suicidal thoughts among patients taking the antibody. But its former collaborator is remaining optimistic about the once-promising treatment, tentatively moving toward an FDA filing.
Amgen is giving Neulasta its first TV advertising push in years--just months before its patent expires. But there's a case to be made for promoting the biologic this late in the game.
Amgen, which has been looking to steal market share from Celgene's Pomalyst in treating multiple myeloma, has won a new FDA approval for Kyprolis that will help it in that fight.
Novartis' Sandoz may have the first FDA-approved biosimilar in Zarxio, but it doesn't have permission to launch--and it won't be getting that until September, the country's top patent court ruled Tuesday.
Amgen's new cholesterol fighter may be second in line for FDA approval in the U.S. But in Europe, it's officially first. Amgen's PCSK9 contender Repatha slipped past Sanofi and Regeneron's Praluent to win E.U. approval Tuesday, with a broad label that could help it build sales quickly.
A cadre of drugmakers is pressing toward late-stage trials with new injectable treatments in the long-stagnant field of migraine therapy, racing to capitalize on what analysts say is a multibillion-dollar market.
Amgen's manufacturing and R&D sites in Colorado are officially on the block and the company is hoping another drugmaker will be interested in buying them.